Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLantern Pharma Inc

Lantern Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.5679 USD 0.04 ( 6.75%)
Last update at 2026-11-06T21:10:00Z
VOLUME
100738
Market Cap
21.73M

Momentum Score

…

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.50
Low
0.58
High
52 Week Price Range
1.11
Low
4.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.53
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
12.02
ROE
-400.92%
Net Debt
74.12M
ROCE
-262.00%
Diluted EPS TTM
-1.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.12M -20.78M -15.96M -14.26M -12.36M
Net income -17.12M -20.78M -15.96M -14.09M -12.30M
Selling general administrative 6.46M 6.09M 5.98M 5.83M 5.02M
Selling and marketing expenses - - 5977.45M - -
Gross profit -0.02M -0.19M -0.17M - -
Reconciled depreciation 0.02M 0.02M 0.01M 0.01M 0.01M
Ebit -17.12M -20.78M -15.96M -14.43M -12.59M
Ebitda -17.10M -20.76M -15.79M -14.42M -12.58M
Depreciation and amortization 0.02M 0.02M 0.17M 0.01M 0.01M
Operating income -17.98M -22.22M -17.88M -14.43M -12.59M
Other operating expenses 17.98M 22.22M 17.88M 14.43M 12.59M
Interest expense - - - 0.20M 0.22M
Interest income 0.44M 0.74M 0.57M 0.20M 0.07M
Net interest income 0.44M 0.74M 0.57M 0.20M 0.07M
Income tax expense - - -0.00M -0.17M -0.07M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 17.98M 22.22M 17.70M 14.43M 12.59M
Cost of revenue 0.02M 0.19M 0.17M - -
Total other income expense net 0.86M 1.44M 1.92M 0.17M 0.23M
Net income from continuing ops -17.12M -20.78M -15.16M -14.26M -12.36M
Net income applicable to common shares - - - -14.26M -12.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.04M 25.57M 43.65M 58.84M 73.95M
Other current assets 0.65M 1.23M 1.18M 3.53M 1.99M
Total liab 4.50M 4.38M 2.74M 2.80M 2.38M
Total stockholder equity 6.53M 21.19M 40.91M 56.04M 71.57M
Other current liab -78.46M 4.14M 2505.21M 2.75M 2.17M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -93.15M -76.03M -55.24M -39.28M -25.02M
Other assets - 0.00M - 0.02M 1.02M
Cash 4.42M 7.51M 21.94M 37.20M 51.52M
Total current liabilities 4.50M 4.33M 2.68M 2.80M 2.33M
Current deferred revenue - - -2505.21M - -
Net debt 74.12M -7.27M -21.70M -37.15M -51.32M
Short term debt 78.54M 0.19M 0.17M 0.05M 0.15M
Short long term debt total 78.54M 0.24M 0.23M 0.05M 0.20M
Other stockholder equity 99.65M 97.06M 96.26M 95.69M 96.69M
Property plant equipment - - - 0.05M 0.22M
Total current assets 10.80M 25.25M 43.34M 58.72M 72.72M
Net tangible assets - - - 56.04M 71.57M
Short term investments 5.70M 16.50M 19.36M 17.99M 19.20M
Net receivables 0.03M 0.10M 0.86M 0.59M 0.18M
Accounts payable 4.42M 4.14M 2.51M 2.75M 2.17M
Accumulated other comprehensive income 0.03M 0.15M -0.11M -0.37M -0.09M
Common stock total equity - - - 0.00M -
Retained earnings total equity - - - -39.28M -
Non currrent assets other -107.24M 0.04M 0.03M 0.02M 1.02M
Non current assets total 0.23M 0.32M 0.31M 0.11M 1.23M
Capital lease obligations 0.08M 0.24M 0.23M 0.05M 0.20M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 11.06M 3.37M -0.58M 0.21M -19.52M
Change to liabilities - - - 0.58M 1.62M
Total cashflows from investing activities 11.06M 3.37M -0.93M 0.18M -19.53M
Total cash from financing activities 1.50M 0.07M -0.50M -2.18M 63.42M
Change to operating activities - - - -1.19M -1.02M
Net income -17.12M -20.78M -15.96M -14.26M -12.36M
Change in cash -3.09M -14.43M -15.81M -14.78M 33.30M
Begin period cash flow 7.51M 21.94M 37.74M 52.52M 19.23M
End period cash flow 4.42M 7.51M 21.94M 37.74M 52.52M
Total cash from operating activities -15.68M -17.81M -14.35M -12.77M -10.59M
Issuance of capital stock 1.62M 0.00M - 0.00M 69.00M
Depreciation 0.02M 0.02M 0.01M 0.01M 0.01M
Other cashflows from investing activities 11031.29M 20.65M -0.00M - -
Change to account receivables - -0.18M -0.16M - -
Sale purchase of stock - - -0.50M -2.48M -
Other cashflows from financing activities -0.14M 0.07M -0.93M 0.30M -5.58M
Change to netincome - - - 1.74M 1.16M
Capital expenditures 0.00M 0.01M 0.02M 0.03M 0.02M
Cash flows other operating - - - -0.92M -
Cash and cash equivalents changes - - - -14.77M -
Change in working capital 0.64M 2.23M 0.54M -0.61M 0.60M
Stock based compensation 0.65M 0.73M 1.07M 1.19M 0.96M
Other non cash items 0.14M -0.01M -0.01M 0.91M 0.09M
Free cash flow -15.68M -17.83M -14.37M -12.80M -10.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
LTRN
Lantern Pharma Inc		 0.04
6.75%		 0.57 - - - 9.74 0.21
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Lantern Pharma Inc

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

1920 McKinney Avenue, Dallas, TX, United States, 75201

972 277 1136

https://www.lanternpharma.com

16

Name Title Year Born
Mr. Panna Sharma PH.D. Pres, CEO & Director 1971
Mr. David R. Margrave CFO & Sec. 1961
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 1955
Nicole Leber Investor Relations Associate, Fin. & Admin. Coordinator NA
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor NA
Mr. Panna Sharma PH.D. President, CEO & Director 1971
Mr. David R. Margrave CFO & Secretary 1961
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator NA
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations NA
Mr. Panna Sharma President, CEO & Director 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…